

# Thomas Reiberger

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4593079/thomas-reiberger-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268  
papers

6,470  
citations

41  
h-index

69  
g-index

349  
ext. papers

9,035  
ext. citations

5.5  
avg, IF

6  
L-index

#	Paper	IF	Citations
268	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis.. <i>Platelets</i> , <b>2022</b> , 1-8	3.6	0
267	Effect of liver resection-induced increases in hepatic venous pressure gradient on development of postoperative acute kidney injury.. <i>BMC Nephrology</i> , <b>2022</b> , 23, 21	2.7	1
266	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
265	Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	0
264	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.. <i>Advances in Medical Sciences</i> , <b>2022</b> , 67, 154-162	2.8	0
263	Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	
262	Response to Letter to the EditorWritten by Dr. Isabelle Ollivier-Hourmand.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	
261	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , <b>2022</b> , 100513	10.3	1
260	The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis.. <i>Hepatology Communications</i> , <b>2021</b> ,	6	5
259	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	7
258	Baveno VII - Renewing consensus in portal hypertension.. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	53
257	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 723-732	0.7	25
256	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 1485-1493	5.3	0
255	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
254	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	17
253	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	11
252	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , <b>2021</b> ,	11.2	1

251	Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 452-460	2.3	2
250	When Is a Critically Ill Cirrhotic Patient Too Sick to Transplant? Development of Consensus Criteria by a Multidisciplinary Panel of 35 International Experts. <i>Transplantation</i> , <b>2021</b> , 105, 561-568	1.8	14
249	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , <b>2021</b> , 70, 1758-1767	19.2	19
248	PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
247	Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00326	4.2	6
246	Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1000-1001	13.4	
245	Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249785	3.7	0
244	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	2
243	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	1
242	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , <b>2021</b> , 10, 48	1.2	1
241	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 427-437	5.3	3
240	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , <b>2021</b> , 15, 1160-1173	8.8	1
239	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2670-2677	5.6	7
238	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1660-1675	6	4
237	Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach. <i>Clinics in Liver Disease</i> , <b>2021</b> , 25, 311-326	4.6	1
236	Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 2281-2298	5.6	0
235	Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252274	3.7	2
234	Outcomes of an HCV elimination program targeting the Viennese MSM population. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 635-640	2.3	1

233	Polyploidy control in hepatic health and disease. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1177-1191	13.4	4
232	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2159-2170	7.9	7
231	Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease". <i>Journal of Hepatology</i> , <b>2021</b> , 75, 234-236	13.4	
230	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	4
229	Letter to the Editor: Perioperative Presentation of COVID-19 in a Liver Transplant Recipient. <i>Hepatology</i> , <b>2021</b> , 73, 868-869	11.2	1
228	Author response to Letter to the Editor: MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , <b>2021</b> , 41, 221-222	7.9	
227	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , <b>2021</b> , 73, 1275-1289	11.2	20
226	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 819-828	13.4	33
225	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 345-352	3.3	
224	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1097-1108	13.4	41
223	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , <b>2021</b> , 41, 799-809	7.9	8
222	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 421-431	2.3	2
221	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 335-344	5.3	2
220	Letter to Lavian and colleagues. <i>European Journal of Radiology</i> , <b>2021</b> , 134, 109449	4.7	
219	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , <b>2021</b> ,	19.2	16
218	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	15
217	Author's reply to "Thromboelastometry in patients with advanced chronic liver disease: a complex interplay". <i>Hepatology International</i> , <b>2021</b> , 15, 522-524	8.8	
216	Adequate scattergram interpretation increases the reliability of automated polymorphonuclear (pmn) cell counts from ascitic fluid of patients with liver cirrhosis. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> , 43, O176-O180	2.5	

215	Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 731-746	3.4	4
214	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	
213	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , <b>2021</b> , 41, 2249-2268	7.9	8
212	The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality. <i>Hepatology</i> , <b>2021</b> , 74, 1533-1545	11.2	7
211	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , <b>2021</b> , 41, 2622-2634	7.9	0
210	Letter to Niezen and colleagues. <i>Liver International</i> , <b>2021</b> , 41, 2525-2526	7.9	
209	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256544	3.7	1
208	Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1243-1262	6.1	5
207	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
206	Nuclear receptors in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2021</b> , 1867, 166235	6.9	4
205	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , <b>2021</b> ,	5.3	4
204	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , <b>2021</b> , 57, 99	6.9	1
203	Nachbetreuung von PatientInnen mit Sustained virologic response. <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , <b>2020</b> , 18, 110-117	0	
202	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , <b>2020</b> , 14, 1093-1103	8.8	1
201	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 1713-1724	7.9	8
200	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 205-212	6.1	9
199	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. <i>Gastroenterology</i> , <b>2020</b> , 159, 534-548.e11	13.3	29
198	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 240-255	7.3	24

197	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
196	Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229239	3.7	10
195	Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , <b>2020</b> , 40, 2228-2241	7.9	5
194	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 1415-1426	7.9	10
193	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 113-120	13.4	29
192	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , <b>2020</b> , 40, 787-796	7.9	6
191	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 321-331	5.3	13
190	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1140-1150	13.4	41
189	Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	14
188	Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244514	3.7	3
187	PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. <i>EMBO Reports</i> , <b>2020</b> , 21, e50893	6.5	12
186	Measurement of the Hepatic Venous Pressure Gradient (HVPG) <b>2020</b> , 447-450		
185	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , <b>2020</b> ,	1.6	23
184	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , <b>2020</b> , 132, 1-11	2.3	7
183	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2712-2718	4	1
182	Does the Functional Liver Imaging Score Derived from Gadoteric Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. <i>Radiology</i> , <b>2020</b> , 294, 98-107	20.5	23
181	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 533-542	6.9	9
180	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , <b>2020</b> , 40, 393-404	7.9	9

179	The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. <i>Hepatology</i> , <b>2020</b> , 72, 584-594	11.2	10
178	Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , <b>2020</b> , 40, 894-904	7.9	8
177	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
176	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <i>Hepatology International</i> , <b>2020</b> , 14, 1083-1092	8.8	6
175	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 842-854	13.4	108
174	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. <i>BMC Medicine</i> , <b>2020</b> , 18, 336	11.4	0
173	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1473-1479	3.3	2
172	Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1174-1185	5.3	6
171	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 2797-2807	7.9	11
170	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	4
169	Hepatitis C Virus RNA Is Commonly Detectable in Rectal and Nasal Fluids of Patients With High Viremia. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1292-1299	11.6	6
168	Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. <i>Liver International</i> , <b>2020</b> , 40, 988-989	7.9	4
167	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 313-327.e6	6.9	41
166	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , <b>2020</b> , 71, 1023-1036	11.2	67
165	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 194-204	7.9	19
164	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , <b>2019</b> , 131, 395-403	2.3	5
163	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3642-3651	4	5
162	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. <i>PLoS ONE</i> , <b>2019</b> , 14, e0216677	3.7	13

161	Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment: Is It Worth Measuring?. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 174-186	1	22
160	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 2164-2172	4	8
159	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , <b>2019</b> , 33, 197-206	5.8	9
158	Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. <i>European Radiology</i> , <b>2019</b> , 29, 6600-6610	8	10
157	High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 507-516	5.3	14
156	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1144-1151	3.3	14
155	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 651-661	5.3	2
154	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1323-1333	6.1	61
153	Animal models of portal hypertension. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2019</b> , 1865, 1019-1030	6.9	14
152	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , <b>2019</b> , 39, 127-135	7.9	32
151	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , <b>2019</b> , 39, 2374-2385	7.9	24
150	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 11674	4.9	5
149	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 850-858	5.3	8
148	Vascular Targets for the Treatment of Portal Hypertension. <i>Seminars in Liver Disease</i> , <b>2019</b> , 39, 483-501	7.3	12
147	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , <b>2019</b> , 157, 705-719.e18	13.3	50
146	Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 308-329	5.6	36
145	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224506	3.7	5
144	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 5897-5917	5.6	35



143	Portal Hypertension after Liver Transplantation Causes and Management. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 59-66	1	3
142	Detection of Various Microplastics in Human Stool: A Prospective Case Series. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 453-457	8	357
141	Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction. <i>Scientific Reports</i> , <b>2019</b> , 9, 18541	4.9	9
140	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2019</b> , 8, 203-217	9.1	31
139	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , <b>2019</b> , 49, 201-211	5.1	8
138	Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study. <i>Liver International</i> , <b>2019</b> , 39, 290-298	7.9	20
137	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1162-1169	6.1	17
136	Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment-A multicenter retrospective study. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1056-1061	3.3	17
135	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 6220	4.9	99
134	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , <b>2018</b> , 154, 1694-1705.e4	13.3	90
133	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 966-979	6.1	25
132	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , <b>2018</b> , 38, 1427-1436	7.9	16
131	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 980-988	6.1	44
130	Early TIPS bei Varizenblutungen Ergebnisse aus der klinischen Routine. <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , <b>2018</b> , 16, 29-35	0	
129	Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. <i>Gastroenterology</i> , <b>2018</b> , 154, 1550-1551	13.3	9
128	Management of portal hypertension before and after liver transplantation. <i>Liver Transplantation</i> , <b>2018</b> , 24, 112-121	4.5	12
127	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , <b>2018</b> , 38, 1036-1044	7.9	20
126	Role of diuretics in the harmful effects of beta blockers in patients with ascites. Author's reply. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 102-103	3.3	1

125	Impact of patatin-like phospholipase domain containing 3 rs738409C/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 451-459	6.1	13
124	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , <b>2018</b> , 8, 9372	4.9	24
123	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , <b>2018</b> ,	1.6	3
122	Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. <i>Visceral Medicine</i> , <b>2018</b> , 34, 270-275	2.4	20
121	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , <b>2018</b> , 2018, 8489709	3.2	6
120	Liver disease in adults with $\alpha$ -antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 710-718	5.3	16
119	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. <i>PLoS ONE</i> , <b>2018</b> , 13, e0189414	3.7	18
118	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , <b>2018</b> , 130, 446-455	2.3	26
117	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 10054-10068	3.3	14
116	Liver Fibrosis and Metabolic Alterations in Adults with Homozygous Alpha1-antitrypsin Deficiency (PiZZ Genotype). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2018</b> , 56, E2-E89	1.6	
115	Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 86-94	6.1	22
114	Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 291-295	2.2	6
113	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. <i>Hepatology</i> , <b>2018</b> , 67, 1516-1530	11.2	30
112	Transferrin as a predictor of survival in cirrhosis. <i>Liver Transplantation</i> , <b>2018</b> , 24, 343-351	4.5	19
111	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , <b>2018</b> , 130, 105-114	2.3	11
110	Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?. <i>Current Hepatology Reports</i> , <b>2018</b> , 17, 301-315	1	13
109	De-Ritis Ratio Improves Long-Term Risk Prediction after Acute Myocardial Infarction. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	12
108	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , <b>2018</b> , 44, 2578-2586	3.5	6

107	Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 315, G484-G494	5.1	26
106	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 184-190	4	12
105	Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. <i>Gut</i> , <b>2017</b> , 66, 1347-1349	19.2	16
104	Letter: sustained virological response and liver healing - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1173-1174	6.1	2
103	Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 139-149	6.4	63
102	Reply to: "Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?". <i>Journal of Hepatology</i> , <b>2017</b> , 67, 880-881	13.4	
101	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 1008-1015	2.4	6
100	Metabolic preconditioning protects BSEP/ABCB11 mice against cholestatic liver injury. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 95-101	13.4	37
99	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 724-733	13.4	87
98	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 135-158	2.3	76
97	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 309-316	2.2	10
96	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1360-1367	3.3	15
95	Reply to: "Non selective beta blockers in cirrhosis". <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1343-1344	13.4	
94	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. <i>Investigative Radiology</i> , <b>2017</b> , 52, 462-469	10.1	11
93	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 517-526	2.3	8
92	Acid-base disorders in liver disease. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1062-1073	13.4	48
91	Beta adrenergic blockade and decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 849-859	13.4	95
90	Beta blockers and cirrhosis, 2016. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 3-10	3.3	50

89	Low 25-OH-vitaminD levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 8-15	2.3	28
88	The role of TIPS in the management of liver transplant candidates. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 1100-1107	5.3	11
87	Liver fibrosis assessment and treatment initiation within a systematic screening program among HIV/HIV-coinfected patients. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, e28-e56	1.6	
86	The novel point shear-wave elastography method ElastPQ is accurate for non-invasive evaluation of liver fibrosis and portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, e28-e56	1.6	
85	ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, e28-e56	1.6	
84	Liver Capsule: FXR agonists against liver disease. <i>Hepatology</i> , <b>2016</b> , 64, 1773	11.2	11
83	The profile of platelet granule released molecules affects postoperative liver regeneration. <i>Hepatology</i> , <b>2016</b> , 63, 1675-88	11.2	54
82	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , <b>2016</b> , 128, 414-20	2.3	1
81	Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis <b>2016</b> , 333-339		1
80	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , <b>2016</b> , 10, 424-35	8.8	40
79	Assessment of response to beta-blockers by expression of Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1265-73	13.4	21
78	Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. <i>Infection</i> , <b>2016</b> , 44, 93-101	5.8	11
77	Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. <i>PLoS ONE</i> , <b>2016</b> , 11, e0145319	3.7	3
76	Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152910	3.7	26
75	Secondary Prophylaxis in Special Patient Populations <b>2016</b> , 317-332		
74	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , <b>2016</b> , 30, 1039-47	3.5	32
73	The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , <b>2016</b> , 36, 1649-1656	7.9	6
72	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4061	1.8	15

71	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 692-699	13.4	190
70	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1194-9	3.3	1
69	An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. <i>Nature Protocols</i> , <b>2015</b> , 10, 1264-74	18.8	63
68	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , <b>2015</b> , 35, 381-90	7.9	90
67	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. <i>Liver International</i> , <b>2015</b> , 35, 1393-402	7.9	9
66	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , <b>2015</b> , 277, 903-12	20.5	46
65	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , <b>2015</b> , 35, 876-85	7.9	29
64	Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 707-18	6.1	38
63	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1657-65	4	33
62	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. <i>Liver International</i> , <b>2015</b> , 35, 2115-20	7.9	36
61	Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123948	3.7	6
60	Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. <i>Ultrasound in Medicine and Biology</i> , <b>2015</b> , 41, 2340-9	3.5	20
59	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. <i>Hepatology</i> , <b>2015</b> , 61, 1591-602	11.2	276
58	Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 729-35	7	9
57	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , <b>2015</b> , 35, 2121-8	7.9	52
56	Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0116768	3.7	20
55	Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137096	3.7	5
54	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143429	3.7	19

53	Chronic hepatitis C: treat everyone now or stratify by disease?. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2015</b> , 61, 11-9	1.6	7
52	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , <b>2014</b> , 34, 69-77	7.9	25
51	Reversion and conversion of interferon- $\gamma$ release assay results in HIV-1-infected individuals. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 729-33	7	22
50	Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 508-16	3.4	11
49	Reply: To PMID 24631577. <i>Gastroenterology</i> , <b>2014</b> , 147, 942	13.3	1
48	Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. <i>AIDS Patient Care and STDs</i> , <b>2014</b> , 28, 221-7	5.8	10
47	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. <i>Hepatology</i> , <b>2014</b> , 59, 1435-47	11.2	136
46	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1135-42	13.4	30
45	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , <b>2014</b> , 9, e95515	3.7	20
44	PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension. <i>PLoS ONE</i> , <b>2014</b> , 9, e108544	3.7	27
43	The association of smoking with IGRA and TST results in HIV-1-infected subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2014</b> , 18, 709-16	2.1	5
42	Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. <i>Ultraschall in Der Medizin</i> , <b>2014</b> , 35, 528-33	3.8	60
41	Revisiting predictors of virologic response to PEGIFN $\alpha$ -1b/ RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 33-41	3.4	12
40	Nonselective $\beta$ blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Gastroenterology</i> , <b>2014</b> , 146, 1680-90.e1	13.3	257
39	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 407-14	1.6	5
38	Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. <i>PLoS ONE</i> , <b>2014</b> , 9, e110503	3.7	43
37	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , <b>2013</b> , 33, 561-8	7.9	15
36	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 911-21	13.4	211

35	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , <b>2013</b> , 125, 200-19	2.3	36
34	The influence of portal pressure on the discordance between absolute CD4+ cell count and CD4+ cell percentage in HIV/hepatitis C virus-coinfected patients. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 904-5	11.6	7
33	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , <b>2013</b> , 62, 1634-41	19.2	214
32	P2.045 Serial Testing with an Interferon-Gamma Release Assay in HIV-1-Infected Individuals. <i>Sexually Transmitted Infections</i> , <b>2013</b> , 89, A101.3-A102	2.8	
31	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , <b>2013</b> , 27, 2707-14	3.5	12
30	Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , <b>2013</b> , 27, 227-32	3.5	37
29	Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e66831	3.7	11
28	Suppression of HBV by tenofovir in HBV/HIV coinfecting patients: a systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2013</b> , 8, e68152	3.7	57
27	IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. <i>European Journal of Clinical Investigation</i> , <b>2012</b> , 42, 599-606	4.6	23
26	The "pegylated" story continues--perhaps because both ends (a and b) are true?. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 226-8; author reply 229	13.4	
25	The risk of infections in HIV-HCV coinfecting patients during antiviral therapy with pegIFN+RBV. <i>Journal of Infection</i> , <b>2012</b> , 65, 142-9	18.9	9
24	von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , <b>2012</b> , 56, 1439-47	11.2	116
23	Letter: sorafenib in portal hypertension [authors' reply]. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 994-995	6.1	1
22	Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 801-10	3.4	51
21	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience. <i>Wiener Klinische Wochenschrift</i> , <b>2012</b> , 124, 395-402	2.3	79
20	Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. <i>Journal of Gastroenterology</i> , <b>2012</b> , 47, 561-8	6.9	83
19	The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 83-91	6.1	66
18	Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 556-9	11.6	32

17	Prognostic value of indeterminate IFN- $\gamma$ release assay results in HIV-1 infection. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 2767-9	9.7	17
16	A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1327-34	1.6	26
15	Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. <i>PLoS ONE</i> , <b>2012</b> , 7, e43143	3.7	33
14	Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 602-8.e1	6.9	53
13	Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 815-24	1.6	29
12	Molecular epidemiology of chronic hepatitis B virus infection in Greece. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 245-52	19.7	15
11	Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfecting patients. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 1802-6	7	15
10	Research update for articles published in EJCI in 2008. <i>European Journal of Clinical Investigation</i> , <b>2010</b> , 40, 770-789	4.6	0
9	Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 156-60	7	12
8	Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfecting patient. <i>Journal of Clinical Virology</i> , <b>2010</b> , 49, 131-3	14.5	43
7	HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 400-9	3.4	59
6	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. <i>European Journal of Clinical Investigation</i> , <b>2009</b> , 39, 65-71	4.6	14
5	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 865-73	13.4	85
4	Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 902-6	3.3	23
3	Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. <i>European Journal of Clinical Investigation</i> , <b>2008</b> , 38, 421-9	4.6	13
2	IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 969-76	1.6	32
1	IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV-HCV Coinfection. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 969-976	1.6	65